Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PARIS

Financiado

Cerrado

PHYSICIAN AIDED RECONSTITUTION OF THE IMMUNE SYSTEM

Unwanted immune responses to self-tissues and transplants have a major impact on human health and wealth. Their management has required long-term immunosuppressive drugs which penalise the whole immune system. The big challenge ha... ver más

31/07/2018

UOXF

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UOXF

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Tumor-Treg-Targeting Training Network for the education of the next generation sc... 1M€ Cerrado

SAF2013-42772-R TERAPIA ANTITUMORAL BASADA EN LINFOCITOS T MODIFICADOS GENET... 121K€ Cerrado

TOLERANCE Targeting innate immunity to induce TOLERANCE in transplanta... 3M€ Cerrado

SI Structural and functional characterization of the ICOS ICOSL... 225K€ Cerrado

CPP2021-008475 Valorización de una terapia antígeno-específica para el trat... 639K€ Cerrado

SAFEIMMUNOSUPPRESS Development of immunosuppressive treatments with better safe... 150K€ Cerrado

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Unwanted immune responses to self-tissues and transplants have a major impact on human health and wealth. Their management has required long-term immunosuppressive drugs which penalise the whole immune system. The big challenge has been to understand how the individual is naturally tolerant to self, and to exploit this knowledge for treatments better targeted to the relevant antigens. Since 1980 the applicant’s laboratory have, in rodent models, defined mechanisms of acquired tolerance, and used monoclonal antibodies to transiently block lymphocyte function, or deplete lymphocytes with the goal of establishing tolerance therapeutically. This led to the discovery of infectious tolerance where tolerance was shown to require regulatory CD4+FoxP3+ T cells. Although efficacious in rodent models, equivalent blockading antibodies for man, although available, have not been commercialised by the pharmaceutical industry. To deplete lymphocytes in man, our laboratory has also developed the anti-CD52 monoclonal antibody, CAMPATH-1H. This was the first humanised therapeutic antibody (Alemtuzumab/Lemtrada) and is being actively pursued for multiple sclerosis and stem cell and organ transplantation. Although lymphocyte depletion has clearly proven to be clinically useful, it has not, when used alone, permitted tolerance to transplanted organs or allowed for durable immune reprogramming in autoimmune disease. This proposal seeks to understand how to build on the benefits of lymphocyte depletion with CAMPATH-1H, and promote tolerance by exploiting tolerance–promoting mechanisms learned from our studies of co-receptor/co-stimulation blockade. The novel approach taken by this project is to investigate and manipulate the reconstitution phase of lymphocyte recovery through Physician Aided Reconstitution of the Immune System (PARIS), by aiming to contain those T-cells that mediate damage whilst empowering competing regulatory T-cells.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores